S1717Referred to Committee

Ensuring Patient Access to Critical Breakthrough Products Act of 2025

Share:
Introduced
In Committee
3
Passed One Chamber
4
Passed Both
5
Signed into Law
119th
Congress
2025-05-12
Introduced
5
Cosponsors
S
ⓘ
Type

Sponsor

Todd Young
Todd Young
Republican · IN · Senator
Votes with party: 74.6% (851 recorded votes)

Full profile: /officials/Y000064

Source: Congress.gov · FEC

Cosponsors (5)

Members who have signed on to support this bill since introduction. Source: Congress.gov.

5 cosponsors on record at Congress.gov. The named list is syncing into Govwatch and will appear here shortly — view on Congress.gov in the meantime.

Latest Action

The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →

Read twice and referred to the Committee on Finance.

2025-05-12

Source: Congress.gov

Committee Activity

Previously

Plain-English Summary

The legislation would allow patients faster access to certain new drugs and medical devices that show promise in treating serious or life-threatening conditions, even before they complete all standard FDA approval testing. This could benefit patients with diseases like cancer or rare conditions who have limited treatment options, though it may involve some additional risk since these products haven't undergone the full approval process. The changes would primarily affect pharmaceutical and medical device companies, patients, and the FDA's approval procedures.

AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.

Subjects

Health
Full bill text is not yet cached locally.
Open text viewRead on Congress.gov

Related legislation

Bills by the same sponsor or covering overlapping subjects.